Recce Pharmaceuticals Management
Management criteria checks 2/4
Recce Pharmaceuticals' CEO is James Graham, appointed in Aug 2020, has a tenure of 3.75 years. total yearly compensation is A$774.73K, comprised of 71.1% salary and 28.9% bonuses, including company stock and options. directly owns 3.32% of the company’s shares, worth A$4.13M. The average tenure of the management team and the board of directors is 3.7 years and 5.5 years respectively.
Key information
James Graham
Chief executive officer
AU$774.7k
Total compensation
| CEO salary percentage | 71.1% |
| CEO tenure | 3.8yrs |
| CEO ownership | 3.3% |
| Management average tenure | 3.7yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now
Nov 01
Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation
Feb 13We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely
Jul 28Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans
Dec 07We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely
Aug 03Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans
Mar 08Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares
Feb 01Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$11m |
| Sep 30 2023 | n/a | n/a | -AU$12m |
| Jun 30 2023 | AU$775k | AU$551k | -AU$13m |
| Mar 31 2023 | n/a | n/a | -AU$14m |
| Dec 31 2022 | n/a | n/a | -AU$15m |
| Sep 30 2022 | n/a | n/a | -AU$13m |
| Jun 30 2022 | AU$548k | AU$328k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$10m |
| Dec 31 2021 | n/a | n/a | -AU$8m |
| Sep 30 2021 | n/a | n/a | -AU$11m |
| Jun 30 2021 | AU$2m | AU$294k | -AU$14m |
| Mar 31 2021 | n/a | n/a | -AU$13m |
| Dec 31 2020 | n/a | n/a | -AU$13m |
| Sep 30 2020 | n/a | n/a | -AU$9m |
| Jun 30 2020 | AU$216k | AU$187k | -AU$4m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$3m |
| Sep 30 2019 | n/a | n/a | -AU$3m |
| Jun 30 2019 | AU$177k | AU$155k | -AU$3m |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | n/a | n/a | -AU$2m |
| Sep 30 2018 | n/a | n/a | -AU$2m |
| Jun 30 2018 | AU$160k | AU$142k | -AU$2m |
| Mar 31 2018 | n/a | n/a | -AU$2m |
| Dec 31 2017 | n/a | n/a | -AU$3m |
| Sep 30 2017 | n/a | n/a | -AU$3m |
| Jun 30 2017 | AU$159k | AU$145k | -AU$3m |
Compensation vs Market: James's total compensation ($USD514.29K) is above average for companies of similar size in the Australian market ($USD296.63K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Graham
3.8yrs
Tenure
AU$774,727
Compensation
Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.1yrs | AU$369.85k | 0.15% A$ 187.2k | |
| CEO, MD & Executive Director | 3.8yrs | AU$774.73k | 3.32% A$ 4.1m | |
| Chief Scientific Director & Executive Director | 3.7yrs | AU$539.34k | 1.33% A$ 1.7m | |
| Principal Quality Chemist & Executive Director | no data | AU$306.76k | 0.15% A$ 183.9k | |
| Principal Engineer & Head of Manufacturing | no data | AU$319.12k | 0.033% A$ 41.0k | |
| Chief Medical Advisor & Independent Non Executive Director | no data | AU$72.50k | 0.062% A$ 77.4k | |
| Chief Financial Officer | 6.5yrs | no data | no data | |
| Head of Marketing | 4.3yrs | no data | no data | |
| Company Secretary | 1.7yrs | no data | no data |
3.7yrs
Average Tenure
Experienced Management: RCE's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.1yrs | AU$369.85k | 0.15% A$ 187.2k | |
| CEO, MD & Executive Director | 8.9yrs | AU$774.73k | 3.32% A$ 4.1m | |
| Chief Scientific Director & Executive Director | 8.9yrs | AU$539.34k | 1.33% A$ 1.7m | |
| Principal Quality Chemist & Executive Director | 4.8yrs | AU$306.76k | 0.15% A$ 183.9k | |
| Chief Medical Advisor & Independent Non Executive Director | 3.8yrs | AU$72.50k | 0.062% A$ 77.4k | |
| Non-Executive Director | 1.7yrs | AU$392.15k | 0.013% A$ 15.8k |
5.5yrs
Average Tenure
Experienced Board: RCE's board of directors are considered experienced (5.5 years average tenure).